Press Release Overview
On July 9, 2026, Ajanta Pharma Limited issued a press release from Mumbai, India, via PRNewswire, stating that India is at a pivotal moment in obesity and metabolic health management. The release notes that India hosts one of the world’s largest overweight and obese populations, a burden that is driving higher prevalence of type 2 diabetes, cardiovascular disease, fatty liver disease, and other metabolic disorders.
Emerging Trends Shaping Obesity Care
Ajanta Pharma identified five key trends expected to define obesity care in India over the coming decade.
1. Obesity as a Chronic Disease – Medical experts are increasingly classifying obesity as a chronic condition influenced by genetics, physiology, environment, behaviour, and lifestyle, prompting more structured, evidence‑based treatment pathways.
2. Earlier Intervention – The industry is moving from reactive treatment after complications arise to proactive, earlier‑stage interventions aimed at reducing long‑term health risks and improving outcomes.
3. Digital Patient Support – Success will rely on adherence, education, and ongoing support; digital health platforms, remote consultations, patient‑education tools, medication reminders, and lifestyle coaching are projected to become integral to obesity management.
4. Personalized Nutrition and Lifestyle Programs – There will be a growing emphasis on individualized plans that combine medical therapy with tailored nutrition guidance, physical‑activity recommendations, and behavioural support, requiring multidisciplinary collaboration among physicians, dietitians, fitness professionals, and patient‑support teams.
5. Integrated Metabolic Health – The focus will shift from weight‑loss‑only conversations to broader outcomes such as glycaemic control, cardiovascular risk reduction, quality of life, and overall metabolic well‑being, positioning obesity care as a central component of cardiometabolic risk management.
Ajanta Pharma’s Strategic Initiatives
To align with these trends, Ajanta Pharma announced investments in patient‑awareness campaigns, healthcare‑professional engagement, and digital support solutions designed to improve treatment adherence and long‑term outcomes. The company disclosed the expansion of its obesity management portfolio with Ozanta®, a semaglutide‑based therapy, and indicated that it is exploring additional patient‑support programmes, expert‑led education initiatives, and digital engagement platforms.
Executive Quote
"The future of obesity management will be defined not only by scientific advancements but by how effectively we support patients throughout their journey. Building awareness, improving access to information, and strengthening patient engagement will be critical to long‑term success," said Mr. Pourus Vakil, President – India Business, Ajanta Pharma.
About Ajanta Pharma Limited
Ajanta Pharma is a speciality pharmaceutical formulation company focused on branded generic business across India, Asia, and Africa, with a presence in more than 30 countries. Many of its products are first‑to‑market and lead in their sub‑therapeutic segments. The company also operates in the United States generic market and maintains institutional business in Africa. Its state‑of‑the‑art R&D centre is located in Mumbai, and it runs seven world‑class manufacturing facilities in India. More information is available at www.ajantapharma.com.
Disclaimer
The press release is provided under an arrangement with PRNewswire; PTI assumes no editorial responsibility for its content.